文献速递造血干细胞移植与细胞治疗

移植后环磷酰胺与巨细胞病毒感染风险增加相关:CIBMTR分析

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.
PubMed 文献 · Blood · 2021-01-01

基于CIBMTR 2012-2017年数据,比较HaploCy、SibCy与SibCNI三组移植后180天CMV感染累积发生率分别为42%、37%、23%(P<.001),PTCy暴露与CMV感染风险升高相关,且CMV感染可能削弱PTCy对慢性GVHD的保护作用。

要点

  • 移植后180天CMV感染累积发生率:HaploCy 42%、SibCy 37%、SibCNI 23%。
  • 无论供者类型,PTCy暴露者CMV感染风险显著高于CNI方案。
  • PTCy受者发生CMV感染与慢性GVHD风险升高相关(P=.006)。

核心结论

  • PTCy无论供者类型均与CMV感染发生率升高相关,并放大血清阳性状态的风险。
  • CMV感染可能抵消PTCy对慢性GVHD的保护作用。

研究设计与样本

  • 回顾性分析CIBMTR 2012-2017年登记数据,纳入HaploCy 757例、SibCy 403例、SibCNI 1605例。

主要发现

  • 移植后180天CMV感染累积发生率分别为HaploCy 42%、SibCy 37%、SibCNI 23%(P<.001)。
  • CMV感染风险在CMV血清阳性受者中最高,但PTCy受者无论供者类型风险均显著升高(HaploCy HR 50.3、SibCy HR 47.7、SibCNI HR 24.4,P<.001)。
  • D+/R-患者CMV感染风险亦增加。
  • 在R+或发生CMV感染者中,HaploCy组总生存更差、非复发死亡率更高。
  • 复发不受CMV感染或血清状态影响。

临床怎么用

  • 对所有接受PTCy的移植患者应考虑 aggressive 预防策略以降低CMV感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prior studies suggest increased cytomegalovirus (CMV) infection after haploidentical donor transplantation with posttransplant cyclophosphamide (HaploCy). The role of allograft source and posttransplant cyclophosphamide (PTCy) in CMV infection is unclear. We analyzed the effect of graft source and PTCy on incidence of CMV infection, and effects of serostatus and CMV infection on transplant outcomes. We examined patients reported to the Center for International Blood and Marrow Transplantation Research between 2012 and 2017 who had received HaploCy (n = 757), matched related (Sib) with PTCy (SibCy, n = 403), or Sib with calcineurin inhibitor-based prophylaxis (SibCNI, n = 1605). Cumulative incidences of CMV infection by day 180 were 42%, 37%, and 23%, respectively (P < .001). CMV disease was statistically comparable. CMV infection risk was highest for CMV-seropositive recipients (R+), but significantly higher in PTCy recipients regardless of donor (HaploCy [n = 545]: hazard ratio [HR], 50.3; SibCy [n = 279]: HR, 47.7; SibCNI [n = 1065]: HR, 24.4; P < .001). D+/R- patients also had increased risk for CMV infection. Among R+ or those developing CMV infection, HaploCy had worse overall survival and nonrelapse mortality. Relapse was unaffected by CMV infection or serostatus. PTCy was associated with lower chronic graft-versus-host disease (GVHD) overall, but CMV infection in PTCy recipients was associated with higher chronic GVHD (P = .006). PTCy, regardless of donor, is associated with higher incidence of CMV infection, augmenting the risk of seropositivity. Additionally, CMV infection may negate the chronic GVHD protection of PTCy. This study supports aggressive prevention strategies in all receiving PTCy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Goldsmith SR, Abid MB, Auletta JJ, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021. PMID: 33657221. doi:10.1182/blood.2020009362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。